Clinical Trials Browser

OTHER × Interventional × olaparib × Clear all

NCT02755844 2026-05-27

ENDOLA

Phase 1/2 Completed

Endometrial Neoplasms

NCT06177171 2026-05-27

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Phase 1 Recruiting

BRCA1 Mutation

NCT02308072 2026-05-22

ORCA-2

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT02693535 2026-05-15

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT04042831 2026-05-15

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Phase 2 Active not recruiting

32 enrolled 15 charts

Gastrointestinal

Bile Duct Neoplasms

NCT05255653 2026-05-15

RAINBO

Phase 2/3 Recruiting

Endometrial Neoplasms

NCT04614909 2026-05-14

Study of Pamiparib in Newly Diagnosed and rGBM

Phase EARLY_PHASE1 Completed

Glioblastoma

NCT03047135 2026-05-12

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Phase 2 Active not recruiting

51 enrolled 8 charts

Prostate

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06217757 2026-05-05

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05379972 2026-05-04

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

Phase 2 Active not recruiting

9 enrolled 8 charts

Gastrointestinal

Stomach Neoplasms

NCT05156268 2026-04-27

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

Phase 2 Completed

GynecologicSarcoma

Endometrial Carcinosarcoma

NCT03682289 2026-04-23

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT03162627 2026-04-15

Selumetinib and Olaparib in Solid Tumors

Phase 1 Active not recruiting

Breast Neoplasms

NCT06607692 2026-04-14

LUPARPED

Phase 1/2 Recruiting

CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT03462342 2026-04-13

CAPRI

Phase 2 Completed

High Grade Serous Carcinoma

NCT05887609 2026-04-13

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Phase 2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06130254 2026-04-09

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Phase 1 Terminated

Other solid neoplasmThoracic

Advanced Solid Tumor

NCT02679963 2026-04-06

PIPSeN

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05524935 2026-04-01

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Phase 2 Recruiting

Uveal Melanoma

NCT03786796 2026-03-30

ORCHID

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06580314 2026-03-24

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Phase 3 Recruiting

Ovarian Neoplasms

NCT03787680 2026-03-23

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Phase 2 Active not recruiting

49 enrolled 11 charts

Prostatic Neoplasms

NCT07486687 2026-03-20

PLANET

Phase 3 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03742245 2026-03-16

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT05340413 2026-03-16

RADIOLA

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07018622 2026-03-11

DAPA-ARMOR

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors

NCT07460180 2026-03-10

PROOV

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04748042 2026-03-06

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT05188508 2026-03-06

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Phase 2 Recruiting

Glioma

NCT04090567 2026-03-05

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT05463848 2026-03-04

Surgical Pembro +/- Olaparib w TMZ for rGBM

Phase 2 Recruiting

Glioblastoma

NCT04005690 2026-02-27

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Phase EARLY_PHASE1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04742075 2026-02-27

DOVACC

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT02787642 2026-02-25

RADIOSARP

Phase 1 Completed

41 enrolled 15 charts

Sarcoma

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT03943173 2026-02-25

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

Phase EARLY_PHASE1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04417062 2026-02-25

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Phase 2 Active not recruiting

Osteosarcoma

NCT07382544 2026-02-25

Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

Phase 1 Recruiting

Other solid neoplasm

Advanced Cancer

NCT03641755 2026-02-23

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT04065269 2026-02-20

ATARI

Phase 2 Active not recruiting

GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT03579316 2026-02-18

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03263650 2026-02-17

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Phase 2 Active not recruiting

Prostate Cancer, Hereditary, 7, Prostatic Neoplasms

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04780945 2026-02-17

FAB

Phase 2 Terminated

Ovarian Neoplasm Epithelial

NCT02624973 2026-02-12

PETREMAC

Phase 2 Active not recruiting

Breast Neoplasms

NCT03085147 2026-02-12

A Dye for the Detection of Cancer of the Tongue and Mouth

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07407452 2026-02-12

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Phase 2 Not yet recruiting

Ovarian Neoplasms

NCT03851614 2026-02-09

DAPPER

Phase 2 Active not recruiting

Leiomyosarcoma